RxDoctor Payments Data

Lori Williams, MD

Internal Medicine · Estero, FLNPI 1437133287

Payments from drug & device makers

$404in general payments, 2019–2025

Across 10 payments — averaging $40.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$123
  • Eisai Inc.$122
  • TG Therapeutics, Inc.$83
  • Amarin Pharma, Inc.$19
  • Alkermes, Inc.$17
  • GSK$15
  • plus $25 from 2 others

What the payments were for

  • Travel & lodging$12330%
  • Food & beverage$28170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$404 in reported general payments places this provider in the 50th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$68,547
Medicare patients
309
Services billed
1,038

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide68$86,358
EliquisApixaban30$39,648
MounjaroTirzepatide28$31,770
ProliaDenosumab16$25,232
JardianceEmpagliflozin18$22,912
XareltoRivaroxaban22$21,738
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$9,590
SynthroidLevothyroxine Sodium56$4,832
Levothyroxine Sodium318$4,031
Rosuvastatin Calcium299$3,664
Estradiol30$3,049
Atorvastatin Calcium341$2,776
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$2,340
Olmesartan Medoxomil70$1,896
Valsartan67$1,831

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$39,64830 claims
GSKTrelegy Ellipta$15$9,59013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Estero

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →